Atomo Diagnostics Ltd (ASX: AT1) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Atomo Diagnostics Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $81.74 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 568.60 million
Earnings per share -0.011
Dividend per share N/A
Year To Date Return -34.43%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Atomo Diagnostics Ltd (ASX: AT1)
Latest News

AT1 ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Atomo Diagnostics Ltd

Atomo Diagnostics Limited is a medical device company. Its Rapid Diagnostic Test devices are used both by healthcare professionals and by consumers to screen for a range of diseases and medical conditions

AT1 Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
29 Nov 2021 $0.20 $0.00 0.00% 635,561 $0.20 $0.21 $0.20
26 Nov 2021 $0.20 $0.00 0.00% 471,741 $0.21 $0.21 $0.20
25 Nov 2021 $0.21 $0.02 10.53% 1,426,277 $0.20 $0.21 $0.20
24 Nov 2021 $0.19 $0.01 5.41% 1,901,848 $0.18 $0.20 $0.18
23 Nov 2021 $0.19 $-0.01 -5.13% 4,514,390 $0.20 $0.20 $0.18
22 Nov 2021 $0.20 $-0.02 -9.30% 1,508,726 $0.21 $0.22 $0.20
19 Nov 2021 $0.22 $0.00 0.00% 2,392,470 $0.21 $0.22 $0.20
18 Nov 2021 $0.22 $0.01 4.76% 653,718 $0.21 $0.22 $0.21
17 Nov 2021 $0.21 $0.00 0.00% 1,435,631 $0.21 $0.22 $0.20
16 Nov 2021 $0.21 $-0.01 -4.65% 1,184,091 $0.22 $0.22 $0.21
15 Nov 2021 $0.22 $-0.02 -8.70% 2,813,231 $0.23 $0.24 $0.22
12 Nov 2021 $0.23 $0.00 0.00% 447,126 $0.24 $0.24 $0.23
11 Nov 2021 $0.23 $0.00 0.00% 1,185,762 $0.23 $0.24 $0.22
10 Nov 2021 $0.24 $-0.02 -8.00% 1,716,178 $0.25 $0.27 $0.24
09 Nov 2021 $0.25 $0.03 13.33% 2,098,949 $0.23 $0.26 $0.23
08 Nov 2021 $0.23 $-0.03 -12.00% 3,176,134 $0.25 $0.25 $0.23
05 Nov 2021 $0.25 $-0.01 -3.85% 2,493,919 $0.26 $0.26 $0.24
04 Nov 2021 $0.26 $-0.01 -3.77% 5,819,930 $0.28 $0.28 $0.24
03 Nov 2021 $0.27 $-0.02 -7.14% 910,466 $0.28 $0.28 $0.27
02 Nov 2021 $0.28 $0.02 7.55% 2,175,975 $0.27 $0.29 $0.27
01 Nov 2021 $0.27 $-0.03 -10.34% 3,804,624 $0.29 $0.29 $0.27

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
03 Nov 2021 John Kelly Sell 1 $286,896
As advised by the company. Average price
03 Nov 2021 John Kelly Issued 333 $88,333
Issue of options.
03 Nov 2021 John Kelly Expiry 666 $176,666
Options expired.
09 Apr 2021 Curt LaBelle Exercise 240 $37,500
Exercise of options.
09 Apr 2021 Curt LaBelle Buy 240 $37,500
Exercise of options.
09 Apr 2021 Curt LaBelle Exercise 960 $150,000
Exercise of options.
09 Apr 2021 Curt LaBelle Buy 960 $150,000
Exercise of options.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr Paul Alexander Kasian Non-Executive Director
Dr Kasian is an experienced Executive Director with experience in both domestic and international companies encompassing senior leadership, strategy, investment and risk roles. His other roles have included Chief Investment Officer and Head of Global Financials at HSBC Asset Management, Founding Director of Accordius and Founding Director of Wallara Asset Management. He is also Non-Executive Director of Zucero Therapeutics Ltd and and Eco Systems Ltd. He is chair of the Risk committee.
Ms Constance (Connie) Bernadette Carnabuci Non-Executive Director Feb 2020
Ms Carnabuci has over 35 years of experience advising intellectual property and technology intensive businesses in Australia and across Asia on commercial, corporate and regulatory matters. She is a professional Non-Executive Director and currently serves on the Board and Remuneration Committee of OFX Group Limited (ASX: OFX). Ms Carnabuci is the former General Counsel of the Australian Broadcasting Corporation and a former partner of Mallesons Stephen Jacques and Freshfields Bruckhaus Deringer. She is a member of the Business Advisory Council of the UNSW Business School. She was a Director and the Chair of the NFP, Kids Giving Back, from 2015 to 2018. She is Chair of the People and Culture Committee.
Mr John Perry Keith Non-Executive ChairmanNon-Executive Director Dec 2011
Mr Keith is a Managing Director of BNP Paribas and its financial institutions coverage team. Prior to joining BNP Paribas in 2011, Mr Keith held country management and senior business and coverage positions for Nomura Securities in Sydney and Hong Kong. His career comprises working with supranational, sovereign and institutional clients across all areas of investment and institutional banking. He has also served on the Boards of ASIA Limited, Calliva Limited, Room to Read Australia Foundation and Ascham Foundation. He is a member of the Risk, People and Culture committee.
Mr John Michael Kelly FounderChief Executive OfficerManaging Director Apr 2010
Mr Kelly has more than 20 years of experience in developing and commercialising medical devices to enhance usability and performance, having started with CR Bard in Europe developing Class III implantable cardiology products. Prior to co-founding Atomo in 2010, Mr Kelly acted as the Chief Operating Officer (COO) of Unilife Corporation, which was previously an ASX-listed company (ASX:UNS) and subsequent to his departure, a Nasdaq listed company (NASDAQ:UNIS). At Unilife Corporation, he led the global operations team from 2005 to 2008, developing 'Unifill'. Prior to joining Unilife in 2005, Mr Kelly spent five years at ResMed where he led the New Product Implementation Group and managed the development of the ground-breaking Mirage Swift and Activa mask systems.
Dr Curt Harold LaBelle Non-Executive Director Oct 2016
Dr LaBelle has been involved in the healthcare industry for over 20 years, both operationally and as an investor. Dr LaBelle is President at the Global Health Investment Fund (GHIF), a social impact investment fund. He also serves as a Director on the Boards of Z Optics, Evenovia, Revelation Bio and Atticus Medical. Prior to joining GHIF, Dr LaBelle was Managing Director at Tullis Health Investors and Vice President at Investor Growth Capital. He is a former chairman of Impulse Monitoring (acquired by Nuvasive), Exagen Inc. (NASDAQ:XGN) and a former Director of Sirion Therapeutics (products acquired by Alcon and Bausch), SafeOp Surgical (acquired by AlphaTec) and KAI Pharmaceuticals (acquired by Amgen). Currently, he is Director of Eyenovia Inc. (NASDAQ:EYEN). He is a member of the Risk committee.
Ms Deborah Neff Non-Executive Director Sep 2021
Ms Neff has experience in building businesses and product commercialization in life sciences industry. Currently, she is advising several early-stage companies developing innovative technology to improve patient care. Most recently, she was the CEO of, Evanostics, LLC, a development stage company focused on systems for applications in point-of-care diagnostic testing in forensic and clinical toxicology. Prior to that, she was the Chief Operating Officer at Complete Genomics Inc., a life sciences company in whole genome and exome sequencing. Deborah continues as the principal of a privately held consulting company, DJN Consulting, LLC. that she formed in 2013. Prior to Complete Genomics, Deborah served as the Chief Operating Officer of Pathwork Diagnostics, Inc. and previously as CEO of Predicant Biosciences Inc. Deborah served as the global president of BD Biosciences, a major business segment of Becton Dickinson and Company until 2003. Her work experience at BD Biosciences over 15 years included various management positions including general manager, vice president and director of several business areas. Deborah's work in life sciences has included the areas of cancer diagnostics, immunocytometry and genomics, having establishing a certified clinical laboratory, guiding a molecular diagnostic test through the FDA clearance process, securing reimbursement pathways, and building commercial pipelines. Deborah served as a board member and executive management advisor for Galt Inc. and Vortex Biosciences Inc, and served on the board of BioRad, Inc. She is a former board member of Advanced Medical Optics, Inc. and ForteBio Corporation Inc., boards, which were acquired by Abbott Laboratories and Pall Corporation respectively. Deborah is an Executive Trustee of the UC Davis Foundation Board and Chairs the Global Campaign Leadership Committee. She also chairs the College of Biological Sciences Dean's Leadership Council at the University. Deborah also completed executive programs in marketing, finance, operations, and management at UCLA, Wharton, Stanford, and Harvard business schools.
Ms Gillian Maria Nairn Company Secretary
-
William Souter Chief Financial Officer
-
Mark Smith Chief Operating Officer
-
Gillian Maria Nairn Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Dalraida Holdings Pty Limited 66,160,000 11.64%
Global Health Investment Fund I LLC 64,811,280 11.40%
HSBC Custody Nominees (Australia) Limited 46,427,252 8.17%
Walker Group Holdings Pty Ltd 37,660,718 6.62%
National Nominees Limited 22,976,845 4.04%
J P Morgan Nominees Australia Pty Limited 14,258,766 2.51%
Grand Challenges Canada 11,390,824 2.00%
Liverbird Pty Ltd 10,931,653 1.92%
I D E Pty Ltd 9,032,248 1.59%
Mark Andrew Smith 7,790,224 1.30%
John Michael Kelly 7,370,248 1.30%
Leo James Lynch & Judith Anne Beswick 7,321,121 1.29%
Mr Ian Fredrick Johnson 6,079,560 1.07%
Ruth Karen Devney 5,626,408 0.99%
Citicorp Nominees Pty Limited 5,373,057 0.94%
Bosana Nominees Pty Ltd 5,081,496 0.89%
Sokolov Pty Ltd 4,500,000 0.79%
Poul Damgaard Hansen 4,340,184 0.76%
Miss Lisa Marie Mackenzie 3,351,968 0.59%
Alex Griffiths 3,283,872 0.58%

Profile

since

Note